On January 13, 2020 NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, reported preliminary unaudited revenue results for the fourth quarter and full year 2019 (Press release, NuVasive, JAN 13, 2020, View Source [SID1234553127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth Quarter 2019 Highlights

Revenue of approximately $310 million, increased approximately 8% on both a reported and constant currency basis;
U.S. Spinal Hardware revenue increased approximately 8%;
U.S. Surgical Support revenue increased approximately 3%; and
International revenue increased approximately 14% on a reported and constant currency basis.
Full Year 2019 Highlights

Revenue of approximately $1.17 billion, increased approximately 6% on a reported basis and approximately 7% on a constant currency basis;
U.S. Spinal Hardware revenue increased approximately 7%;
U.S. Surgical Support revenue increased approximately 1%; and
International revenue increased approximately 10% on a reported basis and 12% on a constant currency basis.
NuVasive will report its full financial results for 2019 and provide its financial outlook for 2020 during its earnings announcement planned for late February.

"NuVasive delivered consistent above-market growth in 2019, with growth in the fourth quarter across all business lines," said J. Christopher Barry, chief executive officer of NuVasive. "We made meaningful progress throughout the organization last year, including the launch of differentiated new products and advancing enabling technologies to support our continued leadership in minimally invasive spine surgery."

38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020
NuVasive will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15 at the Westin St. Francis in San Francisco. Mr. Barry will represent the Company in a presentation scheduled for 10:00 a.m. PT/1:00 p.m. ET.

A live webcast of the presentation will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.